Cardiac Dimensions Secures Financing for Studies of Carillon Mitral Contour System
April 26, 2018—Cardiac Dimensions, Inc. announced that it has closed a $39 million Series B financing, which will be used to continue to build clinical evidence for the company's Carillon mitral contour system for the treatment of functional mitral regurgitation (FMR) in patients with heart failure. Clinical activities include continuing the United States pivotal CARILLON trial and completing the follow-up and publication of the randomized, double-blinded REDUCE FMR global study.
According to the company, the Carillon system is designed to offer physicians a safe and easy-to-use option to treat patients earlier in their disease diagnosis, including those with lesser degrees of FMR (MR grade 2+), to slow disease progression and stabilize or improve quality of life.
The Carillon mitral contour system is limited to investigational use in the United States. The Carillon system has CE Mark approval and is available in certain European markets and other key geographies.
The financing round includes new investor, Australia-based Hostplus, venture debt from Oxford Finance LLC, as well as support from existing investors M. H. Carnegie & Co., Arboretum Ventures, Lumira Capital, LSP Health Economics Fund, and Aperture Venture Partners.